Tumor-Associated CD19+CD39− B Regulatory Cells Deregulate Class-Switch Recombination to Suppress Antibody Responses

Subhadip Pati(Bose Institute), Gaurisankar Sa(Bose Institute)
Cancer Immunology Research
December 27, 2022
Cited by 18


Related Papers